Bringing together founders and investors from the life sciences – that is the goal of the “Life Science Investors’ Day” (LSID), which took place for the first time on October 10. The event, which was jointly organized by BioLabs Heidelberg, Heidelberg Startup Partners, the Life Science Accelerator Baden-Württemberg and BioRN, was a complete success with over 100 participants.
To turn good ideas into successful products and services, start-ups in the life sciences need an active network – the initiators and organizers of the Life Science Investors’ Day are convinced of this. “We are delighted about the great interest in the event,” says Johannes Frühauf, founder and CEO of BioLabs. “This event brings together exactly the people who are looking for solutions to the health challenges facing our society.”
“With the event, we are creating an ecosystem where founders and investors from the life sciences can exchange ideas and connect,” said Thomas Prexl, managing director of Heidelberg Startup Partners. “We are pleased that the event, which will take place every year in the future, was so well received.”
Julia Schaft, Managing Director of BioRN added, “The LifeScience Investors’ Day is an effective and meaningful addition to the existing support tools in the regional ecosystem due to the involvement of all network partners:in.”
Ann-Kristin Mueller, Site Director of BioLabs Heidelberg, confirms this: “A good idea without an environment in which it can grow remains just that: a good idea. Only with an ecosystem for founders:inside do they become companies.”
The aim of the series of events is to close gaps in the value chain from technology transfer to the financing of clinical trials. Numerous regional, national and international representatives, primarily from the life sciences and healthcare industries, were present as investors. One of them is investor Martin Raditsch, General Partner of CARMA Fund and Managing Director of Innovectis GmbH. “The Life Science Investors’ Day provides the ideal breeding ground for innovation in this industry,” he said. “The Initiator:s succeeded in organizing a successful event that also provided a stage for numerous cross-sectional technologies, for example from the fields of IT, AI or medical technology. It’s great to see how creative and versatile the life science startup scene is.”
Among the participating startups is Medical Brick with its AI-based screening platform for drug discovery, supported by PMC Services GmbH and ValueData GmbH. “As AI enthusiasts, we are in an early start-up phase with Medical Brick and are therefore looking for exchanges with other start-ups as well as directly with investor:s and potential partner:s from the life science / drug discovery sector,” says Business Lead Caroline Heinzelmann. “The Life Science Investors’ Day was the perfect platform for this. Really top organized – exciting pitches and panels and a great and broad selection of different start-ups and Investor:ins.”
The LSID 2022 marks the start of a series of events of this kind, which enable continuous exchange between investors and founders.
About Heidelberg Startup Partner e. V.
The Heidelberg Startup Partner e. V. is an initiative of Heidelberg’s leading research and educational institutions as well as the Rhine-Neckar Chamber of Industry and Commerce and the Heidelberg Technology Park. The aim of the initiative is to support startups with a technological and knowledge-based background. Based at the Heidelberg Technology Park, the interdisciplinary team of Heidelberg Startup Partners helps founders implement their business models and find financing opportunities. With regular events or specialized workshops, the Heidelberg Startup Partners aim to promote the startup scene and strengthen Heidelberg’s attractiveness for startups in the fields of life sciences, artificial intelligence, virtual reality and IT.
Members of Heidelberg Startup Partner e.V. are the German Cancer Research Center (DKFZ),- EMBLEM, Heidelberg University of Education, SRH University of Applied Sciences, Heidelberg Technology Park, Science Value Heidelberg GmbH and Heidelberg University.
About the Life Science Accelerator Baden-Württemberg
The Life Science Accelerator Baden-Württemberg (http://lifescience-bw.de/) is a joint program of Technologiepark Heidelberg GmbH, Heidelberg Startup Partners e.V., the Department of Economic and Structural Development of the City of Mannheim, MAFINEX Gruenderverbund e.V. and the non-profit Foundation for Medical Innovations in Tübingen.
The program supports scientific and technological start-up teams in Baden-Württemberg focusing on biotechnology, medical technology and digital healthcare. The Life Science Accelerator Baden-Württemberg is funded by the Ministry of Economics, Labor and Housing Baden-Württemberg from the European Social Fund (ESF) and the state of Baden-Württemberg. Additional format: http://lifescience-bw.de/ .
Start-up teams in the Accelerator participate in up to 24 workshops and gain access to experienced mentors and experts from the life sciences and healthcare sectors. Teams can also compete in front of investor:ins and industry partners.
BioRN is the science and business cluster of the Rhine-Main-Neckar region around Heidelberg, one of the strongest biotech and life science hubs in Germany. As a non-profit network, BioRN unites more than 140 members in a unique ecosystem, including top universities, research institutions and technology parks. Ten global pharmaceutical companies have R&D sites or are active in the BioRN network. A large number of small and medium-sized companies, as well as local government organizations and advocacy groups, reinforce the cluster’s excellence. With the vision “making life science matter…and innovation happen!”, BioRN has developed a clear strategy to become the leading European life science cluster and attract global investment and talent. BioRN is also a founding partner of Biolabs Heidelberg, a leading shared lab space for life science and biotech startups that is part of the global BioLabs network. Follow BioRN on Twitter (@BioRNCluster) and LinkedIn. (www.biorn.org)
BioLabs defines itself as a catalyst for growth of new biotech companies, enabling the development of tomorrow’s life science technologies. Young companies are provided with fully equipped and maintained laboratories at BioLabs, the size of which is scalable and grows with the needs of the young company. Likewise, exclusive access to key business services, they benefit from a powerful network of innovators and advisors, as well as site teams with unparalleled experience helping founders navigate the complex operational processes of building a biotech company. Startups often face very similar challenges and therefore benefit enormously from mutual exchange with each other. BioLabs locations are in major innovation hubs in North America, Japan as well as Europe (Paris and Heidelberg). Follow BioLabs on Twitter (@BioLabsHQ) and LinkedIn. (www.biolabs.io)